Thomas Kisby

We aim to exploit the properties of nanomaterials/advanced materials and their interactions with cells and tissues for the development of safe and effective medicines, using advanced clinically-relevant disease models. Our mission is to further the progress of nanomedicine toward clinical translation, particularly in disease areas failed by conventional drugs and therapies such as neurooncology.

More information on the team and our work can be found here: https://nanomedicinelab.com/research/teams/nano-therapeutics/

Tom obtained a BSc in Medical Sciences at the University of Leeds in 2015. During his studies, he conducted an industrial placement year at MedImmune (Astra Zeneca) investigating novel bio-therapies for inflammatory liver disease and fibrosis. 

Tom joined the Nanomedicine Lab as a PhD student funded by the EPSRC & MRC Centre for Doctoral Training in Regenerative Medicine at the University of Manchester. His PhD project investigated in vivo cell reprogramming as a strategy to enhance tissue repair and regeneration using adenoviral vectors for gene tranfer. In December 2019 he was recruited as a postdoctoral researcher funded by an EPSRC International Centre-to-Centre of Excellence grant between the Universities of Manchester and Harvard.

He was appointed as Senior Researcher and Team Leader of the NanoTherapeutics Team in June 2021 investigating the application of 2D and other nanomaterials for advanced cancer therapies and has obtained funding from the MRC Confidence in Concept scheme. 

MSc Nanomedicine by Research

CDT NowNano